Los Angeles Capital Management LLC Has $46.47 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Los Angeles Capital Management LLC grew its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 124.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,790,855 shares of the biotechnology company's stock after purchasing an additional 991,494 shares during the period. Los Angeles Capital Management LLC owned approximately 0.63% of Exelixis worth $46,473,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of EXEL. V Square Quantitative Management LLC purchased a new stake in shares of Exelixis in the third quarter worth approximately $30,000. Park Place Capital Corp acquired a new position in Exelixis in the 2nd quarter worth about $45,000. GAMMA Investing LLC raised its stake in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 1,041 shares in the last quarter. EntryPoint Capital LLC grew its stake in shares of Exelixis by 537.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company's stock valued at $49,000 after buying an additional 1,746 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new stake in Exelixis in the third quarter worth approximately $61,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Stock Up 1.3 %

NASDAQ:EXEL traded up $0.45 during mid-day trading on Friday, reaching $36.25. 2,227,542 shares of the company were exchanged, compared to its average volume of 2,840,695. Exelixis, Inc. has a 12 month low of $19.20 and a 12 month high of $36.60. The stock has a market cap of $10.35 billion, a PE ratio of 23.24, a PEG ratio of 0.90 and a beta of 0.51. The company has a fifty day moving average of $28.07 and a 200 day moving average of $24.74.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million for the quarter, compared to analysts' expectations of $490.31 million. During the same quarter in the previous year, the business posted $0.10 EPS. Exelixis's revenue for the quarter was up 14.3% on a year-over-year basis. On average, equities research analysts anticipate that Exelixis, Inc. will post 1.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on EXEL shares. Morgan Stanley increased their price objective on Exelixis from $26.00 to $28.00 and gave the company an "equal weight" rating in a report on Friday, October 11th. JMP Securities restated a "market outperform" rating and set a $29.00 price target on shares of Exelixis in a report on Friday, October 11th. Guggenheim boosted their price objective on Exelixis from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. The Goldman Sachs Group raised Exelixis to a "strong sell" rating in a report on Tuesday, October 15th. Finally, StockNews.com upgraded Exelixis from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 13th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $31.44.

Insider Buying and Selling

In other news, EVP Jeffrey Hessekiel sold 20,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.79, for a total transaction of $515,800.00. Following the sale, the executive vice president now owns 630,325 shares in the company, valued at $16,256,081.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Exelixis news, EVP Jeffrey Hessekiel sold 20,000 shares of the company's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.79, for a total value of $515,800.00. Following the transaction, the executive vice president now directly owns 630,325 shares in the company, valued at $16,256,081.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Maria C. Freire sold 8,250 shares of the company's stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total value of $219,120.00. Following the completion of the transaction, the director now directly owns 91,007 shares in the company, valued at $2,417,145.92. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 277,281 shares of company stock worth $8,826,761. 2.85% of the stock is owned by insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.